Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months

Obregón, Fernando Moreno; Miramontes-González, José Pablo; Guajardo-Fajardo, Catalina Romo; Nieto, Ángel Luis Muñoz; López-Suárez, J.; Martín-Vallejo, Javier; Arco-Prados, Yolanda; Lucas, María Dolores García de; Jiménez, David León

doi:10.1016/j.diabres.2019.107916

Cited by 11 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HbA1c levels reached nadir at 3 months after dulaglutide initiation, and tended to increase until 12 months; however, HbA1c levels from 3 to 12 months were not statistically signi cant. This trend was consistent with the result from the AWARD trials and real-world studies [9,[23][24][25]. Several studies have evaluated the 12-month glucose-lowering e cacy of dulaglutide in the real-world scenario, and showed reductions in HbA1c of − 0.9 to − 1.0% that were comparable to our data [26,27].…”

Section: Discussionsupporting

confidence: 91%

“…In the present study, the incidence of gastrointestinal side effects, including mainly nausea, vomiting, and dyspepsia, was similar or slightly higher than those reported in previous RCTs and real-world data [25,[30][31][32]. Self-reported hypoglycemia occurred more frequently in our study (13.4%) than in previous studies and meta-analyses [13,33,34], and all of them received sulfonylurea and/or basal insulin.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

Yoon

Hong

Choi

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in the real-world clinical practice.Methods: We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center. The primary efficacy endpoint was a change in glycated hemoglobin (HbA1c) between baseline and 6 months. The secondary endpoints were the percentage of patients achieving HbA1c <7.0% or ≤6.5% and the change of body weight at 6 months. Results: At baseline, the mean HbA1c was 8.7 % (8.8% in the add-on to OAD and 8.5% in the add-on to insulin group). The mean adjusted HbA1c at 6 months decreased by −1.13% in the overall patients (p < 0.001), and by −1.36 and −0.74% in the add-on to OAD and add-on to insulin group, respectively. A significant reduction of −2.9 kg in body weight was observed in the overall patients at 6 months (p < 0.001). Approximately 34.8% and 23.2% of patients achieved HbA1c <7.0% and ≤6.5%, respectively. Higher baseline HbA1c and no previous insulin therapy were associated with good response to dulaglutide on multivariate analysis. In subgroup analysis to evaluate the long-term efficacy of dulaglutide (n=82), the mean adjusted HbA1c decreased by −0.86% from baseline to 12 months (p < 0.001). Mild gastrointestinal issues (23.2%) were the most frequently observed adverse events.Conclusions: Dulaglutide is an effective and durable treatment option as add-on to OAD and basal insulin therapy in Korean patients with T2DM.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 83%

Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

Yoon

Hong

Choi

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In the present study, the incidence of gastrointestinal side effects, including mainly nausea, vomiting, and dyspepsia, was similar or slightly higher than those reported in previous RCTs and real-world data. 25 26 27 28 Self-reported hypoglycemia occurred more frequently in our study (13.4%) than in previous studies and meta-analyses, 13 29 30 and all of them received sulfonylurea and/or basal insulin. Similar to previous studies, all reported cases of hypoglycemia were mild, and no severe hypoglycemia was documented in this study.…”

Section: Discussioncontrasting

confidence: 56%

Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

et al. 2021

View full text Add to dashboard Cite

This study was conducted to evaluate the efficacy and safety of once-weekly dulaglutide therapy as add-on to oral antidiabetic drugs (OADs) and basal insulin in Korean patients with type 2 diabetes mellitus (T2DM) in real-world clinical practice. We retrospectively reviewed the medical records of 112 patients who received dulaglutide in a tertiary referral center. The primary efficacy endpoint was a change in glycated hemoglobin (HbA1c) between baseline and 6 months. The secondary endpoints were the percentage of patients achieving HbA1c <7.0% or ≤6.5% and the change of body weight at 6 months. At baseline, the mean HbA1c was 8.7 % (8.8% in the OAD combination and 8.5% in the basal insulin combination group). The mean adjusted HbA1c at 6 months decreased by −1.13% in all patients (p<0.001), and by −1.36 and −0.74% in the OAD combination and basal insulin combination group, respectively. A significant reduction of −2.9 kg in body weight was observed in all patients at 6 months (p<0.001). Approximately 34.8% and 23.2% of patients achieved HbA1c <7.0% and ≤6.5%, respectively. Higher baseline HbA1c and no previous insulin therapy were associated with positive responses to dulaglutide on multivariate analysis. Mild gastrointestinal issues (23.2%) were the most frequently observed adverse events. Dulaglutide is an effective and durable treatment option as OAD and basal insulin combination therapy in Korean patients with T2DM.

show abstract

“…Moreno Obregón et al. analyzed 163 Spanish patients and found 1.4% (15 mmol/mol) reduction in HbA1c (P < 0.001) and 30 mg/dL reduction in FPG levels (P < 0.001) after 6 months of drug use, both of which were maintained until the follow-up at 2 years ( 18 ). Bodyweight, evaluated every 6 months, showed a continues decrease, resulting in a reduction of 7.27 kg after 2 years (P < 0.001).…”

Section: Discussionmentioning

confidence: 99%

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study

et al. 2022

View full text Add to dashboard Cite

IntroductionType 2 diabetes mellitus (T2DM) is a chronic, progressive disease requiring lifelong treatment, and durable medication is essential for maintaining stable glycemic control. This study aimed to evaluate the long-term efficacy of dulaglutide in participants who have continued the drug for more than one year.MethodsWe conducted a retrospective study on 605 participants, who used dulaglutide for over one year between 2016 and 2020. Changes in glycosylated hemoglobin (HbA1c), fasting plasma glucose, and bodyweight from baseline to last prescription day were assessed. Adherence was evaluated by the proportion of days covered (PDC), and a PDC value ≥ 0.80 was considered adherent.ResultsThe mean age was 54.0 ± 11.1 years, and 46.1% were female. The mean baseline HbA1c, bodyweight, and duration of diabetes were 8.8% (72.7 mmol/mol), 75.6 kg, and 12.2 years, respectively. During the mean follow-up of 33.1 months, HbA1c and bodyweight decreased by 1.28% (14 mmol/mol, P < 0.001) and by 3.19 kg (P < 0.001), respectively. The participants were highly adherent with PDC ≥ 0.80 in 92.4% of the participants.ConclusionIn T2DM patients, long-term dulaglutide treatment was effective in maintaining HbA1c and weight reduction. Dulaglutide could be a favorable option of long-term treatment in real-world clinical practice.

show abstract

Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months

Cited by 11 publications

References 15 publications

Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study

Contact Info

Product

Resources

About

Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months

Cited by 11 publications

References 15 publications

Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

Real-world Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

Real-World Efficacy and Safety of Dulaglutide in Korean Patients with Type 2 Diabetes Mellitus: A Retrospective Study in a Tertiary Referral Center

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study

Contact Info

Product

Resources

About

Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months